Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

EMU149771

Sigma-Aldrich

MISSION® esiRNA

targeting mouse Myb

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41105324
NACRES:
NA.51

description

Powered by Eupheria Biotech

Quality Level

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

AAATTTACACAAAGAAATATCCCAGTATTCCATGTATCTCAGTCACTAAACATACACAGAGAGATTTTTAAAAACCAGGAGAAGCATTATTTTGAATGTTAGCTAAATCCCAAGTAATACTTAATGCAACCCTCTAGGAGCTCATTTGTGGCTAATAATCTTGGAAATATCTTTATTATACTAAACCATTTCATGAGGAGAATTTTGTTGTCAGCTTGCTTGAAAAGTTATTACTGTATGAAATAGTTTTATTGAAAAAATTATATTTTTATTCAGTAATTTAATTTTGTAAATGCCAAATGGAGAAATGTGTTCGCTGCTATGGTTTTAGCCTGTAGTCATGCTGCTAGCTAGTGTCAGGGGGCAATAGAGCTTAGATGGAAAAAAGAGAAAGAGACTCGGTGTTAGATAACGGACTATGCACTAGTATTCCAGACTTTTTTATTTTTATATATATGTACCTTTTCCTTTTGTAATTGGAAAACTTATTTGGGAGAATTTTGCATTTGT

Ensembl | mouse accession no.

NCBI accession no.

shipped in

ambient

storage temp.

−20°C

Gene Information

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

P Basova et al.
Oncogene, 33(39), 4735-4745 (2013-10-15)
PU.1 downregulation within hematopoietic stem and progenitor cells (HSPCs) is the primary mechanism for the development of acute myeloid leukemia (AML) in mice with homozygous deletion of the upstream regulatory element (URE) of PU.1 gene. p53 is a well-known tumor
Likun Li et al.
Science signaling, 7(326), ra47-ra47 (2014-05-23)
Androgen deprivation is the standard treatment for advanced prostate cancer (PCa), but most patients ultimately develop resistance and tumor recurrence. We found that MYB is transcriptionally activated by androgen deprivation therapy or genetic silencing of the androgen receptor (AR). MYB

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service